Avenue Therapeutics (NASDAQ:ATXI) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Tuesday, Zacks.com reports. The brokerage presently has a $7.50 target price on the stock. Zacks Investment Research‘s price objective indicates a potential upside of 19.05% from the stock’s current price.

According to Zacks, “Avenue Therapeutics, Inc. is a specialty pharmaceutical company. It acquires, licenses, develops and commercializes products principally for use in the acute/intensive care hospital setting. Avenue Therapeutics, Inc. is based in New York, United States. “

Separately, HC Wainwright reaffirmed a “hold” rating and set a $6.00 price objective on shares of Avenue Therapeutics in a research note on Friday, December 18th.

NASDAQ:ATXI opened at $6.30 on Tuesday. Avenue Therapeutics has a 1 year low of $2.85 and a 1 year high of $12.34. The stock’s fifty day moving average price is $5.90 and its two-hundred day moving average price is $5.77. The company has a market cap of $105.51 million, a P/E ratio of -11.05 and a beta of 0.71.

Avenue Therapeutics (NASDAQ:ATXI) last issued its quarterly earnings data on Tuesday, March 30th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.06). Equities analysts forecast that Avenue Therapeutics will post -0.3 earnings per share for the current year.

A number of large investors have recently bought and sold shares of the stock. BlackRock Inc. increased its stake in Avenue Therapeutics by 5.5% in the 4th quarter. BlackRock Inc. now owns 361,486 shares of the company’s stock worth $2,150,000 after acquiring an additional 18,744 shares during the last quarter. National Asset Management Inc. increased its position in shares of Avenue Therapeutics by 15.0% in the fourth quarter. National Asset Management Inc. now owns 167,787 shares of the company’s stock worth $999,000 after purchasing an additional 21,900 shares during the last quarter. Northern Trust Corp raised its stake in Avenue Therapeutics by 2.1% in the fourth quarter. Northern Trust Corp now owns 82,691 shares of the company’s stock valued at $492,000 after purchasing an additional 1,726 shares in the last quarter. State Street Corp lifted its position in Avenue Therapeutics by 9.5% during the third quarter. State Street Corp now owns 73,316 shares of the company’s stock valued at $794,000 after purchasing an additional 6,372 shares during the last quarter. Finally, Morgan Stanley grew its stake in Avenue Therapeutics by 270.9% in the 3rd quarter. Morgan Stanley now owns 22,706 shares of the company’s stock worth $246,000 after buying an additional 16,584 shares in the last quarter. 16.39% of the stock is owned by institutional investors.

About Avenue Therapeutics

Avenue Therapeutics, Inc, a specialty pharmaceutical company, acquires, licenses, develops, and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, which is in Phase III clinical trials to treat moderate to moderately severe post-operative pain.

Featured Story: Pattern Day Trader

Get a free copy of the Zacks research report on Avenue Therapeutics (ATXI)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.